Awo Ablo
Director at ORCL
Board
About Awo Ablo
Independent director at Oracle since 2022; age 53 as of the 2025 record date. Currently President at Co-Impact (since March 2025), and previously Executive Vice President, Strategy & Partnerships at the Tony Blair Institute for Global Change (Nov 2022–Mar 2025); her background emphasizes global health, international development, and public-sector engagement (International HIV/AIDS Alliance; Chatham House Global Health Working Group; prior role with BBC World Service Trust). Listed committee assignment: Governance. The Board identifies her as independent.
Past Roles
| Organization | Role | Tenure | Committees/Impact |
|---|---|---|---|
| Co-Impact | President | Mar 2025–present | Global development leadership; focus on public health and cross-sector strategy |
| Tony Blair Institute for Global Change | EVP, Strategy & Partnerships | Nov 2022–Mar 2025 | Government stakeholder engagement; partnerships |
| Tony Blair Institute for Global Change | Executive Director, External Relations | Oct 2017–Nov 2022 | External relations leadership |
| Tony Blair Institute for Global Change | Director, External Affairs | Mar 2017–Oct 2017 | External affairs |
| Tony Blair Africa Governance Initiative | Director of Development & External Relations | May 2016–Mar 2017 | Development and government relations |
External Roles
| Organization | Role | Tenure | Notes |
|---|---|---|---|
| iceaddis (Ethiopian innovation hub) | Advisor | Since 2022 | Early-stage tech/innovation advisory |
| Chatham House | Global Health Working Group member | Not specified | Public health policy input |
Board Governance
- Committee assignments: Governance Committee member; not listed as a chair. Note: committee membership to be refreshed upon election at the 2025 meeting.
- Independence: Board determined Ms. Ablo was independent under NYSE standards during FY2025.
- Attendance and engagement: In FY2025 the Board met eight times and each director attended at least 75% of all Board and applicable committee meetings; non-employee directors held executive sessions after each regularly scheduled Board meeting (four in FY2025). In FY2024, the Board met four times and each director attended at least 75%.
- Governance practices: No per‑meeting fees; robust director stock ownership guidelines; anti‑hedging policy for all; anti‑pledging policy for all except Mr. Ellison (whose pledging is monitored by the Governance Committee).
Fixed Compensation
| Fiscal Year | Cash Fees ($) | Stock Awards ($) | Total ($) |
|---|---|---|---|
| FY2023 | 52,500 | 344,899 | 397,399 |
| FY2024 | 60,659 (includes prorated Governance Committee fees beginning Nov 2023) | 345,391 | 406,050 |
| FY2025 | 67,500 | 345,872 | 413,372 |
Director cash retainer program (FY2025):
- Committee member retainers: Finance & Audit and Compensation $25,000; Governance and Independence $15,000. Board members receive no per‑meeting fees.
- Committee chair retainers: Finance & Audit $50,000 (increased effective Aug 2024), Compensation $25,000, Governance and Independence $15,000.
Performance Compensation
- Equity vehicle: Time‑based RSUs only; no performance‑based equity awards for directors; no per‑meeting fees; no chair equity awards.
- Option awards: None outstanding for Ms. Ablo at FY2025 year end.
| Grant/Status | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
| RSUs granted (#) | 3,303 (granted 5/31/2023; vest 5/31/2024) | 2,986 (granted 5/31/2024; vest 5/31/2025) | 2,114 (granted 5/31/2025; vest 5/31/2026) |
| Option awards outstanding (#) | — | — | — |
| Stock awards fair value ($) | 344,899 | 345,391 | 345,872 |
Other Directorships & Interlocks
- The proxy biography for Ms. Ablo does not list any current public company directorships beyond Oracle; external activities noted are primarily non-profit and advisory roles (Co‑Impact; Tony Blair Institute; iceaddis; Chatham House).
Expertise & Qualifications
- The Board highlights a globally informed perspective from extensive collaboration with senior international government officials; leadership in global health; and deep understanding of public sector and healthcare stakeholder priorities relevant to Oracle’s global government and healthcare customers.
Equity Ownership
| Holder | Beneficial Ownership (shares) | % of Class | Notes |
|---|---|---|---|
| Awo Ablo | 11,453 | <1% | As of Sept 19, 2025 record date |
| Unvested RSUs outstanding at FY2025 year end | 2,114 | — | Granted 5/31/2025; vest 5/31/2026 |
Policy alignment:
- Anti-hedging and anti-pledging policies apply to directors (with the sole pledging exception being Mr. Ellison as disclosed), and robust stock ownership guidelines are in place for directors.
Governance Assessment
- Independence and attendance: Independent under NYSE standards with at least 75% meeting attendance in FY2025; consistent attendance standard in FY2024.
- Committee effectiveness: Governance Committee member; background in public sector engagement and global health adds stakeholder insight to governance and ESG oversight.
- Pay structure and alignment: Director pay is equity‑heavy via time‑based RSUs with annual grants around $345k grant‑date fair value, plus modest cash retainers including committee fees; no performance‑based equity or per‑meeting fees, supporting long‑term alignment without incentivizing short‑term risk.
- Ownership and policies: Beneficial ownership disclosed (11,453 shares) alongside unvested RSUs; anti‑hedging/pledging policies and stock ownership guidelines strengthen alignment.
- Potential conflicts/red flags: No Ms. Ablo‑specific related‑party transaction disclosures identified; the Independence Committee reviews related person transactions and director independence, and the Board affirmed her independence for FY2025.